The National Commission into the Regulation of AI in Healthcare, led by NHS doctors and published on 10 September 2026, identified gaps in the UK regulatory framework for AI-enabled medical devices, particularly around how those devices are monitored and updated after approval. The government's acceptance of all 44 recommendations commits it to addressing those gaps in full.
A UK-wide cross-system board will be established to oversee implementation. The Medicines and Healthcare products Regulatory Agency (MHRA) is simultaneously moving its AI Airlock regulatory sandbox into Phase 3, its first explicit focus on post-market surveillance and lifecycle regulation. The two previous phases built an evidence base for proportionate regulation; Phase 3 extends that work to cover how AI-enabled devices change over time once they are on the market.
Organisations wishing to join the third cohort can attend an application webinar on 22 October 2026. The first wave of participants will be selected in November 2026. MHRA has committed to publishing draft guidance on managing changes to AI-enabled medical devices by December 2026. A government consultation on how to qualify and classify AI-enabled devices is planned for 2027.
AI Airlock has secured three years of additional government funding, providing continuity for a programme that has already demonstrated how regulators, innovators and healthcare partners can work together to build the evidence base for better, proportionate regulation.
Health Innovation Minister James Frith said: “We want all patients to benefit from the life-saving potential of AI, with the confidence that it is safe, effective and properly overseen. We also want to see the NHS harness the best new technologies to give patients faster, better care and give staff more time to focus on patients. But innovation must never come at the expense of patient safety.”
Professor Alastair Denniston, Chair of the National Commission, said the government had listened not only to the Commission but to the more than 12,000 patients, clinicians and members of the public who shaped its recommendations. A full implementation roadmap covering all 44 recommendations is due by Spring 2027.
For medical device manufacturers and AI developers planning UK market entry or managing post-market compliance, the December 2026 MHRA draft guidance and the November 2026 cohort selection are the nearest defined decision points.
To stay across the latest in cloud, AI and enterprise tech analysis from Compare the Cloud, subscribe to our weekly newsletter at https://www.comparethecloud.net/newsletter
